Skip to main content
  Sunday, 01 March 2015
  1 Replies
  6.7K Visits
  Subscribe
Hi! Dr Weinstein, Is it now official that Eculizumab is approved in Ontario for treatment of aHUS, would OHIP only patients (without private insurance) benefit, does one have to establish the compliment mutations to be an eligible candidate. 

  
Hi Venkat,

According to the company, although the drug is indeed approved for usage in aHUS, coverage is determined on a case-by-case basis. And no, approval does not depend on the demonstration of a mutation; demonstrable mutations are often absent in aHUS in 30-50% of cases, making the diagnosis a combination of both clinical and laboratory parameters.

Jordan
  • Page :
  • 1
There are no replies made for this post yet.
Submit Your Response
Upload files or images for this discussion by clicking on the upload button below.
Supported: gif,jpg,png,zip,rar,pdf,jpeg,doc,docx,xls,xlsx
· Insert · Remove
  Upload Files (Maximum 10MB)

Sharing your current location while posting a new question allow viewers to identify the location you are located.

ukidneyisup